Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALBT NASDAQ:APM NASDAQ:ERNA NASDAQ:VRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBTAvalon GloboCare$2.70+3.8%$2.31$1.87▼$11.66$10.37M0.02291,113 shs54,713 shsAPMAptorum Group$1.85-5.6%$1.68$0.46▼$7.49$9.89M0.183.74 million shs190,953 shsERNAErnexa Therapeutics$1.25+5.5%$1.64$1.17▼$22.35$9.55M5.66284,475 shs84,917 shsVRAXVirax Biolabs Group$0.63-2.5%$0.78$0.52▼$3.62$2.74M1.64347,864 shs3.34 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBTAvalon GloboCare-7.14%+10.17%+14.04%-14.19%-30.67%APMAptorum Group-1.01%+14.62%+41.01%+79.83%-31.94%ERNAErnexa Therapeutics-8.53%-4.84%-25.55%-53.36%-94.76%VRAXVirax Biolabs Group+8.42%+13.27%-16.08%-21.10%-75.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBTAvalon GloboCare$2.70+3.8%$2.31$1.87▼$11.66$10.37M0.02291,113 shs54,713 shsAPMAptorum Group$1.85-5.6%$1.68$0.46▼$7.49$9.89M0.183.74 million shs190,953 shsERNAErnexa Therapeutics$1.25+5.5%$1.64$1.17▼$22.35$9.55M5.66284,475 shs84,917 shsVRAXVirax Biolabs Group$0.63-2.5%$0.78$0.52▼$3.62$2.74M1.64347,864 shs3.34 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBTAvalon GloboCare-7.14%+10.17%+14.04%-14.19%-30.67%APMAptorum Group-1.01%+14.62%+41.01%+79.83%-31.94%ERNAErnexa Therapeutics-8.53%-4.84%-25.55%-53.36%-94.76%VRAXVirax Biolabs Group+8.42%+13.27%-16.08%-21.10%-75.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBTAvalon GloboCare 0.00N/AN/AN/AAPMAptorum Group 0.00N/AN/AN/AERNAErnexa Therapeutics 0.00N/AN/AN/AVRAXVirax Biolabs Group 3.00Buy$3.00376.11% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBTAvalon GloboCare$1.33M7.80N/AN/A($11.37) per share-0.24APMAptorum GroupN/AN/AN/AN/A$2.20 per shareN/AERNAErnexa Therapeutics$580K16.46N/AN/A$0.50 per share2.49VRAXVirax Biolabs Group$10K273.46N/AN/A$1.26 per share0.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBTAvalon GloboCare-$7.90M-$19.96N/A∞N/A-1,451.94%N/A-75.12%11/10/2025 (Estimated)APMAptorum Group-$4.27MN/A0.00∞N/AN/AN/AN/AN/AERNAErnexa Therapeutics-$44.54M-$8.31N/A∞N/A-7,652.75%N/A-682.08%11/10/2025 (Estimated)VRAXVirax Biolabs Group-$6.06MN/A0.00∞N/AN/AN/AN/A10/1/2025 (Estimated)Latest VRAX, ERNA, APM, and ALBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ALBTAvalon GloboCareN/A-$2.02N/A-$6.22N/A$0.35 million8/13/2025Q2 2025ERNAErnexa TherapeuticsN/A-$0.61N/A-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBTAvalon GloboCareN/AN/AN/AN/AN/AAPMAptorum GroupN/AN/AN/AN/AN/AERNAErnexa TherapeuticsN/AN/AN/AN/AN/AVRAXVirax Biolabs GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBTAvalon GloboCareN/A0.060.06APMAptorum GroupN/A0.220.22ERNAErnexa TherapeuticsN/A1.811.81VRAXVirax Biolabs GroupN/A7.277.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBTAvalon GloboCare1.42%APMAptorum Group3.80%ERNAErnexa Therapeutics70.55%VRAXVirax Biolabs Group8.61%Insider OwnershipCompanyInsider OwnershipALBTAvalon GloboCare37.30%APMAptorum Group63.99%ERNAErnexa Therapeutics4.49%VRAXVirax Biolabs Group45.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBTAvalon GloboCare53.84 million2.41 millionNot OptionableAPMAptorum Group305.35 million1.93 millionNot OptionableERNAErnexa Therapeutics107.67 million7.33 millionNo DataVRAXVirax Biolabs Group54.34 million2.38 millionNot OptionableVRAX, ERNA, APM, and ALBT HeadlinesRecent News About These CompaniesVirax Biolabs Group Limited (NASDAQ:VRAX) Sees Significant Increase in Short InterestSeptember 13 at 2:54 AM | americanbankingnews.comVirax Biolabs Group Limited (NASDAQ:VRAX) Short Interest UpdateSeptember 6, 2025 | americanbankingnews.comVirax Biolabs (VRAX) Falls 18% on Lack of LeadsAugust 27, 2025 | insidermonkey.comVirax BioLabs Group Limited: Virax Biolabs Partners with Emory University on ViraxImmune Clinical Studies; Readies for FDA Pre-Submission Meeting in Early SeptemberAugust 27, 2025 | finanznachrichten.deVirax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early SeptemberAugust 26, 2025 | prnewswire.comVirax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial StrategyJuly 29, 2025 | prnewswire.comVirax Biolabs Group Limited (VRAX) Latest Stock News & Headlines ...July 22, 2025 | finance.yahoo.comVirax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyJuly 20, 2025 | finanznachrichten.deVirax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyJuly 18, 2025 | prnewswire.comHC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy RecommendationMarch 31, 2025 | msn.comVirax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy RatingMarch 31, 2025 | benzinga.comVirax Biolabs Launches Clinical Study on T Cell DysfunctionMarch 18, 2025 | msn.comVirax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection SyndromesMarch 18, 2025 | prnewswire.comVirax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation MeetingMarch 13, 2025 | prnewswire.comVirax Biolabs to Present at 19th World Immune Regulation MeetingMarch 5, 2025 | prnewswire.comVirax Biolabs Aligns with US Health Department on Vaccine TransparencyFebruary 25, 2025 | tipranks.comVirax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine EfficacyFebruary 25, 2025 | prnewswire.comCosmos Health expands distribution of Avian Influenza kitsJanuary 23, 2025 | msn.comCosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and KuwaitJanuary 23, 2025 | accessnewswire.comACosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC CountriesJanuary 13, 2025 | accesswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesChevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 2025How a Superstore Strategy Fueled MINISO’s 20% Stock SurgeBy Jeffrey Neal Johnson | August 26, 2025Lyft's Billion-Dollar Signal: Why Wall Street Is Betting BigBy Jeffrey Neal Johnson | August 19, 2025Low-Cost Global Exposure: 3 Diversified ETFs for Value InvestorsBy Nathan Reiff | September 2, 2025Is Qualcomm Tesla’s Next Rival in Autonomous Driving?By Sam Quirke | September 9, 2025VRAX, ERNA, APM, and ALBT Company DescriptionsAvalon GloboCare NASDAQ:ALBT$2.70 +0.10 (+3.85%) Closing price 04:00 PM EasternExtended Trading$2.73 +0.03 (+1.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.Aptorum Group NASDAQ:APM$1.85 -0.11 (-5.61%) Closing price 04:00 PM EasternExtended Trading$1.85 0.00 (0.00%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Ernexa Therapeutics NASDAQ:ERNA$1.25 +0.07 (+5.51%) Closing price 04:00 PM EasternExtended Trading$1.25 0.00 (0.00%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Virax Biolabs Group NASDAQ:VRAX$0.63 -0.02 (-2.49%) Closing price 03:59 PM EasternExtended Trading$0.64 +0.01 (+2.36%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
